Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With...
SchizophreniaThe main purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of once weekly dosing of zicronapine, compared to daily dosing of zicronapine.
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
HallucinationsSchizophrenia1 moreThe efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT) This study will use a combination of different MRI modalities (fMRI and DTI) to define with precision rTMS brain-targets in the case of multisensory hallucinations The investigators anticipate that multimodal MRI-guided rTMS will allow a significant improvement in the efficacy of neuromodulation treatment of refractory hallucinations
Transcranial Direct Current Stimulation (tDCS) for Treatment of Negative Syndrome in Patients With...
SchizophreniaTranscranial direct current stimulation (tDCS) showed beneficial effects on cognition in healthy subjects and depressed patients. In this study, patients with treatment resistant negative syndrome in schizophrenia will be treated with direct current stimulation. fMRI measures will be performed.
Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients...
SchizophreniaThe purpose of this study is to explore the safety, tolerability, and potential clinical efficacy of JNJ 40411813 in schizophrenic patients.
Study of Vitamin D in the Severely Mentally Ill
SchizophreniaSchizoaffective DisorderSupplementation of Vitamin D in those with low levels will increase the level and result in some improvement in health and psychopathology measures.
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized...
SchizophreniaThe investigators hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score and Cognitive Assessment Interview).
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in...
SchizophreniaSchizoaffective DisorderLurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective...
SchizophreniaSchizoaffective DisorderLurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).
A Comparison of Long-acting Injectable Medications for Schizophrenia
SchizophreniaSchizoaffective DisorderThe purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of...
SchizophreniaThis multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.